Year 2024 / Volume 116 / Number 7
Editorial
Drug approach to treatment for obesity in adults: perspectives and considerations

353-355

DOI: 10.17235/reed.2024.10206/2023

Javier Escalada,

Abstract
Obesity is considered a chronic disease and a serious public-health issue in Spain, as well as in many other countries, primarily because of it being a significant risk factor for multiple chronic conditions, including diabetes mellitus type 2, cardiovascular disease, respiratory disease, metabolic dysfunction-associated fatty liver disease, gastrointestinal conditions (gastroesophageal reflux, diverticulosis), musculoskeletal difficulties, infertility, and even development of some malignancies such as postmenopausal breast cancer, and colorectal, endometrial, renal, esophageal, pancreatic, hepatic, and gallbladder neoplasms. Furthermore, weight loss, whether as therapy goal or voluntary, has been shown to be beneficial for virtually all these health conditions, the more so the greater weight loss.
Share Button
New comment
Comments

08/07/2024 16:51:31
https://jamanetwork.com/journals/jamasurgery/article-abstract/2820074


References
1 Gutiérrez-González E, García-Solano M, Pastor-Barriuso R, et al. Socio-geographical disparities of obesity and excess weight in adults in Spain: insights from the ENE-COVID study. Front Public Health. 2023 Jul 17:11:1195249. doi:10.3389/fpubh.2023.1195249. eCollection 2023.
2 Aranceta-Bartrina J, Pérez-Rodrigo C, Alberdi-Aresti G, et al. Prevalence of General Obesity and Abdominal Obesity in the Spanish Adult Population (Aged 25-64 Years) 2014-2015: The ENPE Study. Rev Esp Cardiol (Engl Ed). 2016 Jun;69(6):579-87.
3. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019 May;7(5):344-355. doi: 10.1016/S2213-8587(19)30068-3.
4 Wilding JPH, Batterham RL, Calanna S, et al. STEP 1 Study Group. OnceWeekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002.
5 Garvey WT, Batterham RL, Bhatta M, et al. STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 Oct;28(10):2083- 2091.
6 Rubino D, Abrahamsson N, Davies M, et al. STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224
7 Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038
8 Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022 Jun;10(6):393-406. doi: 10.1016/S2213-8587(22)00070-5
9 Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972
10 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389:2221-2232. DOI: 10.1056/NEJMoa2307563
Related articles

Letter to the Editor

GETTEMO position statement on bariatric endoscopic techniques as a voluntary medicine

DOI: 10.17235/reed.2017.5144/2017

Original

Multicenter study on the safety of bariatric endoscopy

DOI: 10.17235/reed.2017.4499/2016

Citation tools
Escalada J. Drug approach to treatment for obesity in adults: perspectives and considerations. 10206/2023


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1072 visits.
This article has been downloaded 230 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 23/12/2023

Accepted: 29/12/2023

Online First: 12/02/2024

Published: 08/07/2024

Article Online First time: 51 days

Article editing time: 198 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology